BloodCancer BiologyPeer-reviewed journal article
The Origin, Diagnosis, and Prognosis of Oligomannose-Type Diffuse Large B Cell Lymphoma
Dylan J. TattertoniD, Maddy L. NewbyiD, Joel D. AlleniD, Benjamin SaleiD, Giorgia ChiodiniD, Patrick J. DurieziD, John Butler, Katy J. McCanniD, David W. ScottiD, Ryan D. MoriniD, Kostiantyn DrevaliD, Andrew John DaviesiD, Dean J. BryantiD, Max CrispiniD, Francesco ForconiiD
Abstract
The acquisition of N-glycosylation sites occupied by oligomannose-type glycans in the immunoglobulin complementarity-determining region (CDR) is an early clonal tumor-specific identifier of follicular lymphoma (FL). CDR-located N-glycosylation sites are also acquired in germinal-center-B-cell-like diffuse large B-cell lymphomas (GCB-DLBCL), but their significance is less defined. We used RNA-seq immunoglobulin assembly to determine the frequency and CDR location of the acquired N-glycosylation sites (AGS) in two large independent DLBCL cohorts. Composition of the glycans occupying the AGS was determined using liquid chromatography-mass spectrometry and correlated with cell-of-origin, FL signature (defined by EZB phenotype or BCL2 translocation), transcript profile, and clinical outcome. CDR-located AGS were observed in 41-46% of GCB-DLBCL but were rare in other DLBCL. Only CDR-located AGS of DLBCL with an FL signature were occupied by oligomannose-type glycans. These DLBCL were termed Mann-type DLBCL. Conversely, the AGS of the other DLBCL were either non-glycosylated or occupied by complex-type glycans. Mann-type status was an independent marker of short progression-free survival and overall survival. In contrast, the other GCB-DLBCL cases, including those with an FL signature but without AGS, had the best outcomes. Mann-type DLBCL overexpressed gene-sets of cell growth, survival, and cycling, and underexpressed proinflammatory and apoptotic pathways, irrespective of concomitant MYC translocations. Acquisition of Mann-type glycans is a highly selective environmental pressure, identifying the most aggressive GCB-DLBCL with an origin related to FL. The detection of AGS in the CDR of GCB-DLBCLs with a BCL2 translocation defines Mann-type DLBCLs, refines prognosis and marks a precise tumor interaction to block early therapeutically. Key pointsO_LIAcquisition of Mann-type glycans is a tumor-specific environmental pressure identifying the most aggressive GCB-DLBCL with an origin related to FL. C_LIO_LIMann-type DLBCL can be diagnosed by the concomitant detection of AGS in the CDR and a BCL2 translocation. C_LI
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: protein structure prediction
- approach: statistical model
- Citations
- 6
- FWCI
- 3.96
- Field percentile
- top 6%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- DC-SIGN Binding to the Surface Ig Oligomannose-type Glycans Promotes Follicular Lymphoma Cell Adhesion and Survival
Giorgia Chiodin, Dylan J. Tatterton, … Francesco Forconi·BloodPeer-reviewed·Jan 20, 2026
- Oligomannosylation and MAN1A1 expression associate strongly with a subset of human cancer types
S. Chatterjee, R. Kawahara, … M. Thaysen-Andersen·bioRxiv·May 8, 2021
- A Germinal Center-Associated Microenvironmental Signature Reflects Malignant Phenotype and Outcome of Diffuse Large B-cell Lymphoma
K. Miyawaki, K. Kato, … K. Akashi·bioRxiv·Nov 7, 2019
- Comprehensive glycoprofiling of oral tumours associates N-glycosylation with lymph node metastasis and patient survival
C. Moretto Carnielli, T. Melo de Lima Morais, … M. Thaysen-Andersen·bioRxiv·Nov 21, 2022
- Nonclassical monocytes are prone to migrate into tumor in diffuse large B-cell lymphoma
S. Le Gallou, F. Lhomme, … M. Roussel·bioRxiv·Apr 10, 2021
- N-linked glycosylation of the M-protein variable region: Glycoproteogenomics reveals a new layer of personalized complexity in multiple myeloma.
P. Langerhorst, M. Baerenfaenger, … J. F. M. Jacobs·bioRxiv·Apr 5, 2023